“…In the context of glargine versus detemir in the treatment of type 2 diabetes, a number of recent studies suggested in addition cost-effectiveness advantages in favour of basal analogue insulin glargine compared with detemir due to improved outcome parameters [ 32 ], [ 33 ], [ 34 ]. This is also an important area for future research to the German-specific setting with regard evaluating the relative costs and benefits of basal-bolus regimes in T2D.…”